Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary (original) (raw)

• Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112, 1419–1428 (1989).
  Article PubMed Google Scholar
• Lublin, F. D. & Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907–911 (1996).
  Article CAS PubMed Google Scholar
• Morales, Y., Parisi, J. E. & Lucchinetti, C. F. The pathology of multiple sclerosis: evidence for heterogeneity. Adv. Neurol. 98, 27–45 (2006).
  PubMed Google Scholar
• Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707–717 (2000).
  Article CAS PubMed Google Scholar
• Andersson, P. B., Waubant, E., Gee, L. & Goodkin, D. E. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch. Neurol. 56, 1138–1142 (1999).
  Article CAS PubMed Google Scholar
• Kieseier, B. C. & Hartung, H. P. Multiple paradigm shifts in multiple sclerosis. Curr. Opin. Neurol. 16, 247–252 (2003).
  Article PubMed Google Scholar
• Weiner, H. L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255 Suppl 1, 3–11 (2008).
  Article CAS PubMed Google Scholar
• Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
  Article CAS PubMed Google Scholar
• Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123, 1174–1183 (2000).
  Article PubMed Google Scholar
• Kuhlmann, T., Lingfeld, G., Bitsch, A., Schuchardt, J. & Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202–2212 (2002).
  Article PubMed Google Scholar
• Peterson, J. W., Bo, L., Mork, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389–400 (2001).
  Article CAS PubMed Google Scholar
• Miller, D. H., Thompson, A. J. & Filippi, M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol. 250, 1407–1419 (2003).
  Article CAS PubMed Google Scholar
• Rovaris, M. et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 124, 2540–2549 (2001).
  Article CAS PubMed Google Scholar
• Rovaris, M. et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage 24, 1139–1146 (2005).
  Article PubMed Google Scholar
• Rovaris, M. et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch. Neurol. 62, 898–902 (2005).
  Article PubMed Google Scholar
• Hafler, D. A. et al. Multiple sclerosis. Immunol. Rev. 204, 208–231 (2005).
  Article CAS PubMed Google Scholar
• Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85, 299–302 (1996).
  Article CAS PubMed Google Scholar
• Weiner, H. L. Multiple sclerosis is an inflammatory T-cell mediated autoimmune disease. Arch. Neurol. 61, 1613–1615 (2004).
  Article PubMed Google Scholar
• McFarland, H. F. & Martin, R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913–919 (2007).
  Article CAS PubMed Google Scholar
• Woodroofe, M. N. & Cuzner, M. L. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5, 583–588 (1993).
  Article CAS PubMed Google Scholar
• Windhagen, A. et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985–1996 (1995).
  Article CAS PubMed Google Scholar
• Selmaj, K., Raine, C. S., Cannella, B. & Brosnan, C. F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87, 949–954 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Hofman, F. M., Hinton, D. R., Johnson, K. & Merrill, J. E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170, 607–612 (1989).
  Article CAS PubMed Google Scholar
• Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G. & Janeway, C. A. Jr. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57–68 (1993).
  Article CAS PubMed Google Scholar
• Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356, 63–66 (1992). Experimental evidence for the use of monoclonal antibodies to α4β1 integrin in EAE.
  Article CAS PubMed Google Scholar
• Kent, S. J. et al. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58, 1–10 (1995).
  Article CAS PubMed Google Scholar
• Theien, B. E. et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995–1006 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Elovaara, I. et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch. Neurol. 57, 546–551 (2000).
  Article CAS PubMed Google Scholar
• Elices, M. J. et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60, 577–584 (1990).
  Article CAS PubMed Google Scholar
• Niino, M. et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59, 748–754 (2006).
  Article CAS PubMed Google Scholar
• Theien, B. E. et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102, 4464–4471 (2003).
  Article CAS PubMed Google Scholar
• Sato, T., Tachibana, K., Nojima, Y., D'Avirro, N. & Morimoto, C. Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J. Immunol. 155, 2938–2947 (1995).
  CAS PubMed Google Scholar
• Ennis, E., Isberg, R. R. & Shimizu, Y. Very late antigen 4-dependent adhesion and costimulation of resting human T cells by the bacterial beta 1 integrin ligand invasin. J. Exp. Med. 177, 207–212 (1993).
  Article CAS PubMed Google Scholar
• O'Connor, P. W. et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62, 2038–2043 (2004). Key clinical trial supporting the effective use of natalizumab in RRMS.
  Article CAS PubMed Google Scholar
• Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006). Key clinical trial supporting the effective use of natalizumab in RRMS.
  Article CAS PubMed Google Scholar
• Kleinschmidt-DeMasters, B. K. & Tyler, K. L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β-1a for multiple sclerosis. N. Engl. J. Med. 353, 369–374 (2005).
  Article CAS PubMed Google Scholar
• Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W. & Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375–381 (2005).
  Article CAS PubMed Google Scholar
• Yousry, T. A. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924–933 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Cyster, J. G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23, 127–159 (2005).
  Article CAS PubMed Google Scholar
• Sawicka, E. et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J. Immunol. 175, 7973–7980 (2005).
  Article CAS PubMed Google Scholar
• Daniel, C. et al. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J. Immunol. 178, 2458–2468 (2007).
  Article CAS PubMed Google Scholar
• Czeloth, N., Bernhardt, G., Hofmann, F., Genth, H. & Forster, R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J. Immunol. 175, 2960–2967 (2005).
  Article CAS PubMed Google Scholar
• Eigenbrod, S., Derwand, R., Jakl, V., Endres, S. & Eigler, A. Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells. Immunol. Invest. 35, 149–165 (2006).
  Article CAS PubMed Google Scholar
• Pebay, A. et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 13, 2067–2076 (2001).
  Article PubMed Google Scholar
• Bassi, R. et al. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53, 621–630 (2006).
  Article PubMed Google Scholar
• Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124–1140 (2006). Key clinical trial supporting the effective use of oral FTY720 in RRMS.
  Article CAS PubMed Google Scholar
• Babbe, H. et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393–404 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Skulina, C. et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl Acad. Sci. USA 101, 2428–2433 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Zang, Y. C. et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172, 5120–5127 (2004).
  Article CAS PubMed Google Scholar
• Biddison, W. E. et al. CD8+ myelin peptide-specific T cells can chemoattract CD4+ myelin peptide-specific T cells: importance of IFN-inducible protein 10. J. Immunol. 160, 444–448 (1998).
  CAS PubMed Google Scholar
• Buckle, G. J., Höllsberg, P. & Hafler, D. A. Activated CD8+ T cells in secondary progressive MS secrete lymphotoxin. Neurology 60, 702–705 (2003).
  Article CAS PubMed Google Scholar
• Killestein, J. et al. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. J. Neuroimmunol. 142, 141–148 (2003).
  Article CAS PubMed Google Scholar
• Waldmann, T. A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 27, 1–18 (2007).
  Article CAS PubMed Google Scholar
• Hayosh, N. S. & Swanborg, R. H. Autoimmune effector cells. IX. Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors. J. Immunol. 138, 3771–3775 (1987).
  CAS PubMed Google Scholar
• Engelhardt, B., Diamantstein, T. & Wekerle, H. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 2, 61–73 (1989).
  Article CAS PubMed Google Scholar
• Bielekova, B. et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl Acad. Sci. USA 101, 8705–8708 (2004). First clinical report of monoclonal anti-CD25 antibody use in RRMS.
  Article CAS PubMed PubMed Central Google Scholar
• Bielekova, B. et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl Acad. Sci. USA 103, 5941–5946 (2006). Excellent paper dissecting the main immune mechanism of action of anti-CD25 monoclonal antibody in MS.
  Article CAS PubMed PubMed Central Google Scholar
• Montalban, X., Wynn, D., Kaufman, K., Wang, M. & Fong, A. Preliminary CHOICE results: a phase 2, randomized, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Mult. Scler. 13, A50 (2007). Most recent clinical trial results supporting anti-CD25 use in RRMS.
  Google Scholar
• Viglietta, V., Baecher-Allan, C., Weiner, H. L. & Hafler, D. A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971–979 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Haas, J. et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35, 3343–3352 (2005).
  Article CAS PubMed Google Scholar
• Huan, J. et al. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81, 45–52 (2005).
  Article CAS PubMed Google Scholar
• Venken, K. et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J. Neurosci. Res. 83, 1432–1446 (2006).
  Article CAS PubMed Google Scholar
• Goker, H., Haznedaroglu, I. C. & Chao, N. J. Acute graft-vs-host disease: pathobiology and management. Exp. Hematol. 29, 259–277 (2001).
  Article CAS PubMed Google Scholar
• Albert, M. H., Yu, X. Z., Martin, P. J. & Anasetti, C. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood 105, 1355–1361 (2005).
  Article CAS PubMed Google Scholar
• Battaglia, M. et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55, 40–49 (2006).
  Article CAS PubMed Google Scholar
• Strauss, L. et al. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 178, 320–329 (2007).
  Article CAS PubMed Google Scholar
• Qu, Y. et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl. Immunol. 17, 153–161 (2007).
  Article CAS PubMed Google Scholar
• Keever-Taylor, C. A. et al. Rapamycin enriches for CD4+CD25+CD27+Foxp3+ regulatory T cells in _ex vivo_-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 9, 144–157 (2007).
  Article CAS PubMed Google Scholar
• Hong, J., Li, N., Zhang, X., Zheng, B. & Zhang, J. Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl Acad. Sci. USA 102, 6449–6454 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Aharoni, R., Teitelbaum, D., Sela, M. & Arnon, R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 94, 10821–10826 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. & Hafler, D. A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105, 967–976 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Neuhaus, O. et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl Acad. Sci. USA 97, 7452–7457 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Karandikar, N. J. et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109, 641–649 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Tennakoon, D. K. et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 176, 7119–7129 (2006).
  Article CAS PubMed Google Scholar
• Aharoni, R., Kayhan, B., Eilam, R., Sela, M. & Arnon, R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl Acad. Sci. USA 100, 14157–14162 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, M., Valenzuela, R. M. & Dhib-Jalbut, S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci. 215, 37–44 (2003).
  Article CAS PubMed Google Scholar
• Ziemssen, T. et al. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J. Neurol. Sci. 233, 109–112 (2005).
  Article CAS PubMed Google Scholar
• Ishikawa, H. et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56, 2103–2109 (2007).
  Article CAS PubMed Google Scholar
• Bresson, D. et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116, 1371–1381 (2006).
  Article CAS Google Scholar
• Ochi, H. et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells. Nature Med. 12, 627–635 (2006). Excellent paper on oral tolerance induction and the mechanism of action of anti-CD3 in EAE.
  Article CAS PubMed Google Scholar
• van Puijvelde, G. H. et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114, 1968–1976 (2006).
  Article CAS PubMed Google Scholar
• Wu, H. Y., Ward, F. J. & Staines, N. A. Histone peptide-induced nasal tolerance: suppression of murine lupus. J. Immunol. 169, 1126–1134 (2002).
  Article CAS PubMed Google Scholar
• Wu, H. Y., Monsonego, A. & Weiner, H. L. The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression. J. Autoimmun. 26, 116–126 (2006).
  Article CAS PubMed Google Scholar
• Fantini, M. C. et al. Transforming growth factor β induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 55, 671–680 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Whitacre, C. C. Sex differences in autoimmune disease. Nature Immunol. 2, 777–780 (2001).
  Article CAS Google Scholar
• Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P. & Moreau, T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339, 285–291 (1998).
  Article CAS PubMed Google Scholar
• Bebo, B. F. Jr et al. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 166, 2080–2089 (2001).
  Article CAS PubMed Google Scholar
• Ito, A. et al. Estrogen treatment down-regulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167, 542–552 (2001).
  Article CAS PubMed Google Scholar
• Voskuhl, R. R. & Palaszynski, K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 7, 258–270 (2001).
  Article CAS PubMed Google Scholar
• Liu, H. Y. et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70, 238–248 (2002).
  Article CAS PubMed Google Scholar
• Polanczyk, M. J. et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173, 2227–2230 (2004).
  Article CAS PubMed Google Scholar
• Polanczyk, M. J., Hopke, C., Vandenbark, A. A. & Offner, H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J. Neurosci. Res. 84, 370–378 (2006).
  Article CAS PubMed Google Scholar
• Sicotte, N. L. et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421–428 (2002).
  Article CAS PubMed Google Scholar
• Faria, A. M. & Weiner, H. L. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13, 143–157 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Weiner, H. L. et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321–1324 (1993). Pioneering clinical trial on oral tolerance induction by myelin antigen therapy in MS.
  Article CAS PubMed Google Scholar
• Metzler, B. & Wraith, D. C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5, 1159–1165 (1993).
  Article CAS PubMed Google Scholar
• Metzler, B. & Wraith, D. C. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 778, 228–242 (1996).
  Article CAS PubMed Google Scholar
• Bai, X. F. et al. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA. J. Neuroimmunol. 80, 65–75 (1997).
  Article CAS PubMed Google Scholar
• Bai, X. F. et al. Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin. Exp. Immunol. 111, 205–210 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Karpus, W. J., Kennedy, K. J., Smith, W. S. & Miller, S. D. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide. J. Neurosci. Res. 45, 410–423 (1996).
  Article CAS PubMed Google Scholar
• Meyer, A. L., Benson, J. M., Gienapp, I. E., Cox, K. L. & Whitacre, C. C. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J. Immunol. 157, 4230–4238 (1996).
  CAS PubMed Google Scholar
• Benson, J. M. et al. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J. Immunol. 162, 6247–6254 (1999).
  CAS PubMed Google Scholar
• Kennedy, K. J., Smith, W. S., Miller, S. D. & Karpus, W. J. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. J. Immunol. 159, 1036–1044 (1997).
  CAS PubMed Google Scholar
• Critchfield, J. M. et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263, 1139–1143 (1994).
  Article CAS PubMed Google Scholar
• Elliott, E. A. et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 98, 1602–1612 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• McFarland, H. I. et al. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J. Immunol. 166, 2116–2121 (2001).
  Article CAS PubMed Google Scholar
• Neville, K. L., Padilla, J. & Miller, S. D. Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS. J. Neuroimmunol. 123, 18–29 (2002).
  Article CAS PubMed Google Scholar
• Sharma, S. D. et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex–peptide complexes. Proc. Natl Acad. Sci. USA 88, 11465–11469 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Warren, K. G., Catz, I., Ferenczi, L. Z. & Krantz M. J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol. 13, 887–895 (2006). Initial clinical evidence supporting the use of synthetic myelin peptides in PPMS.
  Article CAS PubMed Google Scholar
• Miller, S. D. et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol. Rev. 144, 225–244 (1995).
  Article CAS PubMed Google Scholar
• Kennedy, M. K. et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144, 909–915 (1990).
  CAS PubMed Google Scholar
• Kennedy, M. K., Tan, L. J., Dal Canto, M. C. & Miller, S. D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J. Immunol. 145, 117–126 (1990).
  CAS PubMed Google Scholar
• Tan, L. J., Kennedy, M. K., Dal Canto, M. C. & Miller, S. D. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J. Immunol. 147, 1797–1802 (1991).
  CAS PubMed Google Scholar
• Vandenbark, A. A. et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Med. 2, 1109–1115 (1996).
  Article CAS PubMed Google Scholar
• Su, X. M. & Sriram, S. Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein. J. Neuroimmunol. 34, 181–190 (1991).
  Article CAS PubMed Google Scholar
• Tan, L. J., Kennedy, M. K. & Miller, S. D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J. Immunol. 148, 2748–2755 (1992).
  CAS PubMed Google Scholar
• Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. & Kuchroo, V. K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3, 397–405 (1995).
  Article CAS PubMed Google Scholar
• Gaur, A. et al. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. 74, 149–158 (1997).
  Article CAS PubMed Google Scholar
• Anderton, S. M. et al. Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J. Immunol. 161, 3357–3364 (1998).
  CAS PubMed Google Scholar
• Anderton, S. M., Kissler, S., Lamont, A. G. & Wraith, D. C. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur. J. Immunol. 29, 1850–1857 (1999).
  Article CAS PubMed Google Scholar
• Crowe, P. D., Qin, Y., Conlon, P. J. & Antel, J. P. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 48, 758–765 (2000).
  Article CAS PubMed Google Scholar
• Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167–1175 (2000). Phase II clinical trial results on the use of myelin-altered peptide ligand in MS.
  Article CAS PubMed Google Scholar
• Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nature Med. 6, 1176–1182 (2000). Immune mechanism behind the use of myelin-altered peptide ligand in MS.
  Article CAS PubMed Google Scholar
• Weinshenker, B. G., Bass, B., Karlik, S., Ebers, G. C. & Rice, G. P. An open trial of OKT3 in patients with multiple sclerosis. Neurology 41, 1047–1052 (1991).
  Article CAS PubMed Google Scholar
• Ferran, C. et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20, 509–515 (1990).
  Article CAS PubMed Google Scholar
• Kohm, A. P. et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174, 4525–4534 (2005).
  Article CAS PubMed Google Scholar
• Smith, J. A., Tso, J. Y., Clark, M. R., Cole, M. S. & Bluestone, J. A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J. Exp. Med. 185, 1413–1422 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Ochi, H. et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25-LAP+ T cells. Nat. Med. 12, 627–635 (2006).
  Article CAS PubMed Google Scholar
• Ishikawa, H. et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56, 2103–2109 (2007).
  Article CAS PubMed Google Scholar
• Wu, H. Y., Quintana, F. J. & Weiner, H. L. . Nasal anti-CD3 ameliorates lupus by inducing Foxp3−CD4−CD25−LAP+ regulatory T cells that suppress the function of IL-17+CD4+ICOS−CXCR5+ helper T cells. J. Immunol. (in the press) (2008).
• Chatenoud, L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3, 123–132 (2003).
  Article CAS PubMed Google Scholar
• Chatenoud, L. & Bluestone, J. A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7, 622–632 (2007).
  Article CAS PubMed Google Scholar
• Lobell, A. et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 187, 1543–1548 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ruiz, P. J. et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J. Immunol. 162, 3336–3341 (1999).
  CAS PubMed Google Scholar
• Weissert, R. et al. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc. Natl Acad. Sci. USA 97, 1689–1694 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Weiner, L. P. et al. Gene therapy in a murine model for clinical application to multiple sclerosis. Ann. Neurol. 55, 390–399 (2004).
  Article CAS PubMed Google Scholar
• Xu, B. & Scott, D. W. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin. Immunol. 111, 47–52 (2004).
  Article CAS PubMed Google Scholar
• Louie, K. A. et al. Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis. Gene Ther. 12, 1145–1153 (2005).
  Article CAS PubMed Google Scholar
• Garren, H. et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15–22 (2001).
  Article CAS PubMed Google Scholar
• Robinson, W. H. et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nature Biotech. 21, 1033–1039 (2003).
  Article CAS Google Scholar
• Lobell, A. et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol. 170, 1806–1813 (2003).
  Article CAS PubMed Google Scholar
• Ho, P. P. et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J. Immunol. 175, 6226–6234 (2005).
  Article CAS PubMed Google Scholar
• Ben-Nun, A. & Cohen, I. R. Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur. J. Immunol. 11, 949–952 (1981).
  Article CAS PubMed Google Scholar
• Sun, D., Qin, Y., Chluba, J., Epplen, J. T. & Wekerle, H. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T–T cell interactions. Nature 332, 843–845 (1988).
  Article CAS PubMed Google Scholar
• Hafler, D. A., Cohen, I., Benjamin, D. S. & Weiner, H. L. T cell vaccination in multiple sclerosis: a preliminary report. Clin. Immunol. Immunopathol. 62, 307–313 (1992).
  Article CAS PubMed Google Scholar
• Zhang, J., Medaer, R., Stinissen, P., Hafler, D. & Raus, J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261, 1451–1454 (1993).
  Article CAS PubMed Google Scholar
• Medaer, R., Stinissen, P., Truyen, L., Raus, J. & Zhang, J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346, 807–808 (1995).
  Article CAS PubMed Google Scholar
• Correale, J. et al. T cell vaccination in secondary progressive multiple sclerosis. J. Neuroimmunol. 107, 130–139 (2000).
  Article CAS PubMed Google Scholar
• Vandenbark, A. A., Hashim, G. & Offner, H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541–544 (1989).
  Article CAS PubMed Google Scholar
• Howell, M. D. et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246, 668–670 (1989).
  Article CAS PubMed Google Scholar
• Bourdette, D. N. et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J. Immunol. 152, 2510–2519 (1994).
  CAS PubMed Google Scholar
• Vandenbark, A. A., Vainiene, M., Ariail, K., Miller, S. D. & Offner, H. Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes. J. Neurosci. Res. 45, 430–438 (1996).
  Article CAS PubMed Google Scholar
• Gold, D. P. et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J. Neuroimmunol. 76, 29–38 (1997).
  Article PubMed Google Scholar
• Wilson, D. B. et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J. Neuroimmunol. 76, 15–28 (1997).
  Article CAS Google Scholar
• Morgan, E. E. et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. 64, 298–301 (2001).
  Article CAS PubMed Google Scholar
• Raine, C. S., Cannella, B., Hauser, S. L. & Genain, C. P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 46, 144–160 (1999).
  Article CAS PubMed Google Scholar
• Svensson, L. et al. A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination. Eur. J. Immunol. 32, 1939–1946 (2002).
  Article CAS PubMed Google Scholar
• Corcione, A. et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl Acad. Sci. USA 101, 11064–11069 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Cepok, S. et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128, 1667–1676 (2005).
  Article PubMed Google Scholar
• Uccelli, A., Aloisi, F. & Pistoia, V. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26, 254–259 (2005).
  Article CAS PubMed Google Scholar
• Villar, L. M. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115, 187–194 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Qin, Y. et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102, 1045–1050 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Baranzini, S. E. et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 163, 5133–5144 (1999).
  CAS PubMed Google Scholar
• Colombo, M. et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164, 2782–2789 (2000).
  Article CAS PubMed Google Scholar
• Williamson, R. A. et al. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl Acad. Sci. USA 98, 1793–1798 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Owens, G. P. et al. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 171, 2725–2733 (2003).
  Article CAS PubMed Google Scholar
• Qin, Y. et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab. Invest. 83, 1081–1088 (2003).
  Article PubMed Google Scholar
• O'Connor, K. C. et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J. Immunol. 175, 1974–1982 (2005).
  Article CAS PubMed Google Scholar
• Krumbholz, M. et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195–200 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lucchinetti, C. F., Bruck, W. & Lassmann, H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 56, 308 (2004).
  Article PubMed Google Scholar
• Keegan, M. et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366, 579–582 (2005).
  Article PubMed Google Scholar
• Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J. & Lyons, J. A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63–70 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Tokunaga, M. et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44, 176–182 (2005).
  Article CAS Google Scholar
• Sfikakis, P. P. et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123, 66–73 (2007).
  Article CAS PubMed Google Scholar
• Liossis, S. N. & Sfikakis, P. P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin. Immunol. 127, 280–285 (2008).
  Article CAS PubMed Google Scholar
• Pestronk, A. et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry 74, 485–489 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270–1272 (2005).
  Article CAS PubMed Google Scholar
• Stuve, O. et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62, 1620–1623 (2005).
  PubMed Google Scholar
• Monson, N. L., Cravens, P. D., Frohman, E. M., Hawker, K. & Racke, M. K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol. 62, 258–264 (2005).
  Article PubMed Google Scholar
• Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008). Most recent clinical evidence supporting the use of rituximab in RRMS.
  Article CAS PubMed Google Scholar
• Paolillo, A. et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53, 751–757 (1999).
  Article CAS PubMed Google Scholar
• Coles, A., Deans, J. & Compston, A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin. Neurol. Neurosurg. 106, 270–274 (2004).
  Article PubMed Google Scholar
• Coles, A. Efficacy of alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223. Presented at the 59th Annual Meeting of the American Academy of Neurology (AAN); April 28–May 5, 2007; Boston, Mass. Abstract S12.004. AAN web site [online], (2007).
• Coles, A. Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta-1a. The CAMMS223 International Study Group. Mult. Scler. 13, A557 (2007).
  Google Scholar
• Fox, E. et al. Two-years results with alemtuzumab in patients with active relapsing-remitting multiple sclerosis who have failed licensed beta interferon therapies. Mult. Scler. 13, A558 (2007). Clinical trial supporting the use of alemtuzumab in RRMS patients that are unresponsive to interferon.
  Article Google Scholar
• Brunmark, C. et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163–172 (2002). Experimental animal evidence of laquinimod's effectiveness in treating CNS demyelination.
  Article CAS PubMed Google Scholar
• Runstrom, A., Leanderson, T., Ohlsson, L. & Axelsson, B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice. J. Neuroimmunol. 173, 69–78 (2006).
  Article CAS PubMed Google Scholar
• Yang, J. S., Xu, L. Y., Xiao, B. G., Hedlund, G. & Link, H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol. 156, 3–9 (2004).
  Article CAS PubMed Google Scholar
• Polman, C. et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987–991 (2005). Preliminary human clinical data supporting the potential use of laquinimod in RRMS.
  Article CAS PubMed Google Scholar
• Sipe, J. C. et al. Cladribine improves relapsing-remitting MS: a double blind, placebo controlled study. Neurology 48 (Suppl. 2), A340 (1997).
  Google Scholar
• Sipe, J. C. et al. Development of cladribine treatment in multiple sclerosis. Mult. Scler. 1, 343–347 (1996).
  Article CAS PubMed Google Scholar
• Rice, G. P., Filippi, M. & Comi, G. Cladribine and progress.sive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54, 1145–1155 (2000). Preliminary clinical data supporting cladribine therapy in PPMS.
  Article CAS PubMed Google Scholar
• Lukashev M. et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflamatory and neuroprotective modalities. Mult. Scler. 13, A503 (2007).
  Google Scholar
• Kappos L. et al. BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. Mult. Scler. 12, A325 (2006).
  Article Google Scholar
• O'Connor P. W. et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. Neurology 66, 894–900 (2006). Preliminary clinical data supporting the therapeutic potential of teriflunomide in RRMS.
  Article CAS PubMed Google Scholar
• Jonsson, C. A. & Carlsten, H. Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int. Immunopharmacol. 3, 31–37 (2003).
  Article CAS PubMed Google Scholar
• Blaheta, R. A. et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant. Proc. 31, 1250–1252 (1999).
  Article CAS PubMed Google Scholar
• Tran, G. T., Carter, N. & Hodgkinson, S. J. Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis. Int. Immunopharmacol. 1, 1709–1723 (2001).
  Article CAS PubMed Google Scholar
• Ahrens, N., Salama, A. & Haas, J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J. Neurol. 248, 713–714 (2001).
  Article CAS PubMed Google Scholar
• Frohman, E. M., Brannon, K., Racke, M. K. & Hawker, K. Mycophenolate mofetil in multiple sclerosis. Clin. Neuropharmacol. 27, 80–83 (2004).
  Article CAS PubMed Google Scholar
• Vermersch, P. et al. Combination of IFN β-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur. J. Neurol. 14, 85–89 (2007).
  Article CAS PubMed Google Scholar
• Matute, C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol. Med. 12, 289–292 (2006).
  Article CAS PubMed Google Scholar
• Reynolds, A., Laurie, C., Mosley, R. L. & Gendelman, H. E. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 82, 297–325 (2007).
  Article CAS PubMed Google Scholar
• Ganor, Y., Besser, M., Ben-Zakay, N., Unger, T. & Levite, M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol. 170, 4362–4372 (2003).
  Article CAS Google Scholar
• Bolton, C. & Paul, C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J. Pharmacol. Exp. Ther. 282, 397–402 (1997).
  CAS PubMed Google Scholar
• Paul, C. & Bolton, C. Modulation of blood–brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the _N_-methyl-D-aspartate receptor antagonist memantine. J. Pharmacol. Exp. Ther. 302, 50–57 (2002).
  Article CAS PubMed Google Scholar
• Smith, T., Groom, A., Zhu, B. & Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nature Med. 6, 62–66 (2000).
  Article CAS PubMed Google Scholar
• Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med. 6, 67–70 (2000).
  Article CAS PubMed Google Scholar
• Wallstrom, E. et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. 137, 89–96 (1996).
  Article CAS PubMed Google Scholar
• Sarchielli, P., Greco, L., Floridi, A. & Gallai, V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch. Neurol. 60, 1082–1088 (2003).
  Article PubMed Google Scholar
• Pitt, D., Nagelmeier, I. E., Wilson, H. C. & Raine, C. S. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 61, 1113–1120 (2003).
  Article CAS PubMed Google Scholar
• Basso, A. S. et al. Reversal of axonal loss and disability in a mouse model of pregressive multiple sclerosis. J. Clin. Invest. 118, 1532–1543 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gilgun-Sherki, Y., Panet, H., Melamed, E. & Offen, D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res. 989, 196–204 (2003).
  Article CAS PubMed Google Scholar
• Kalkers, N. F., Barkhof, F., Bergers, E., van Schijndel, R. & Polman, C. H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler. 8, 532–533 (2002).
  Article CAS PubMed Google Scholar
• Killestein, J., Kalkers, N. F. & Polman, C. H. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J. Neurol. Sci. 233, 113–115 (2005).
  Article CAS PubMed Google Scholar
• Yong, V. W. et al. The promise of minocycline in neurology. Lancet Neurol. 3, 744–751 (2004).
  Article PubMed Google Scholar
• Yrjanheikki, J. et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA 96, 13496–13500 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med. 6, 797–801 (2000).
  Article CAS PubMed Google Scholar
• Du, Y. et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 14669–14674 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, D. C. et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763–1771 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, S. et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417, 74–78 (2002).
  Article CAS PubMed Google Scholar
• Wells, J. E., Hurlbert, R. J., Fehlings, M. G. & Yong, V. W. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126, 1628–1637 (2003).
  Article PubMed Google Scholar
• Stirling, D. P. et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J. Neurosci. 24, 2182–2190 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C. & Yong, V. W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125, 1297–1308 (2002).
  Article PubMed Google Scholar
• Popovic, N. et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51, 215–223 (2002).
  Article CAS PubMed Google Scholar
• Maier, K. et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis. 25, 514–525 (2007).
  Article CAS PubMed Google Scholar
• Wang, J. et al. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J. Biol. Chem. 279, 19948–19954 (2004).
  Article CAS PubMed Google Scholar
• Yrjanheikki, J., Keinanen, R., Pellikka, M., Hokfelt, T. & Koistinaho, J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl Acad. Sci. USA 95, 15769–15774 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Tikka, T., Fiebich, B. L., Goldsteins, G., Keinanen, R. & Koistinaho, J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580–2588 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kloppenburg, M. et al. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol. 102, 635–641 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Machado, L. S. et al. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 7, 56 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Giuliani, F. et al. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213–221 (2005).
  Article CAS PubMed Google Scholar
• Giuliani, F., Fu, S. A., Metz, L. M. & Yong, V. W. Effective combination of minocycline and interferon-β in a model of multiple sclerosis. J. Neuroimmunol. 165, 83–91 (2005).
  Article CAS PubMed Google Scholar
• Metz, L. M. et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 55, 756 (2004).
  Article PubMed Google Scholar
• Seukeran, D. C., Eady, E. A. & Cunliffe, W. J. Benefit–risk assessment of acne therapies. Lancet 349, 1251–1252 (1997).
  Article CAS PubMed Google Scholar
• Shapiro, L. E., Knowles, S. R. & Shear, N. H. Comparative safety of tetracycline, minocycline, and doxycycline. Arch. Dermatol. 133, 1224–1230 (1997).
  Article CAS PubMed Google Scholar
• Windrem, M. S. et al. Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nature Med. 10, 93–97 (2004).
  Article CAS PubMed Google Scholar
• Nistor, G. I., Totoiu, M. O., Haque, N., Carpenter, M. K. & Keirstead, H. S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49, 385–396 (2005).
  Article PubMed Google Scholar
• Pluchino, S. et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422, 688–694 (2003). Pioneering experimental work on the potential use of neural stem-cell therapy in MS.
  Article CAS PubMed Google Scholar
• Ben-Hur, T. et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia 41, 73–80 (2003).
  Article PubMed Google Scholar
• Einstein, O. et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp. Neurol. 198, 275–284 (2006).
  Article CAS PubMed Google Scholar
• Karussis, D. M. et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J. Immunol. 148, 1693–1698 (1992).
  CAS PubMed Google Scholar
• van Gelder, M., Kinwel-Bohre, E. P. & van Bekkum, D. W. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant 11, 233–241 (1993).
  CAS PubMed Google Scholar
• van Bekkum, D. W. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract. Res. Clin. Haematol. 17, 201–222 (2004).
  Article CAS PubMed Google Scholar
• Burt, R. K. et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102, 2373–2378 (2003).
  Article CAS PubMed Google Scholar
• Inglese, M. et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J. Neurol. Neurosurg. Psychiatry 75, 643–644 (2004).
  CAS PubMed PubMed Central Google Scholar
• Freedman, M. S. & Atkins, H. L. Suppressing immunity in advancing MS: too much too late, or too late for much? Neurology 62, 168–169 (2004).
  Article PubMed Google Scholar
• Blanco, Y., Saiz, A., Carreras, E. & Graus, F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol. 4, 54–63 (2005). Excellent review on the use of autologous HSCT in MS.
  Article PubMed Google Scholar
• Saccardi, R. et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105, 2601–2607 (2005).
  Article CAS PubMed Google Scholar
• Chen, J. T. et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66, 1935–1937 (2006).
  Article CAS PubMed Google Scholar
• Metz, I. et al. Autologous hematopoietic stem cell transplantation: the glass seems to be half full for aggressive, early forms of MS and half empty for advanced MS. Brain 131, e90 (2007).
  Article Google Scholar
• Brown, R. A. et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J. Clin. Oncol. 17, 806–812 (1999).
  Article CAS PubMed Google Scholar
• Filippi, M. et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44, 635–641 (1994).
  Article CAS PubMed Google Scholar
• Brex, P. A. et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346, 158–164 (2002).
  Article PubMed Google Scholar
• Losseff, N. A., Kingsley, D. P., McDonald, W. I., Miller, D. H. & Thompson, A. J. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult. Scler. 1, 218–222 (1996).
  Article CAS PubMed Google Scholar
• Fisher, E. et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59, 1412–1420 (2002).
  Article CAS PubMed Google Scholar
• Sanfilipo, M. P., Benedict, R. H., Sharma, J., Weinstock-Guttman, B. & Bakshi, R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 26, 1068–1077 (2005).
  Article PubMed Google Scholar
• Lin, X., Tench, C. R., Evangelou, N., Jaspan, T. & Constantinescu, C. S. Measurement of spinal cord atrophy in multiple sclerosis. J. Neuroimaging 14, 20S–26S (2004).
  Article PubMed Google Scholar
• Zivadinov, R. & Bakshi, R. Central nervous system atrophy and clinical status in multiple sclerosis. J. Neuroimaging 14, 27S–35S (2004).
  Article PubMed Google Scholar
• De Stefano, N. et al. MR correlates of cerebral atrophy in patients with multiple sclerosis. J. Neurol. 249, 1072–1077 (2002).
  Article PubMed Google Scholar
• Bakshi, R., Dandamudi, V. S., Neema, M., De, C. & Bermel, R. A. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J. Neuroimaging 15, 30S–45S (2005).
  Article PubMed Google Scholar
• Balashov, K. E., Smith, D. R., Khoury, S. J., Hafler, D. A. & Weiner, H. L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl Acad. Sci. USA 94, 599–603 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Comabella, M. et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102, 671–678 (1998).
  Article CAS Google Scholar
• Sorensen, T. L. et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103, 807–815 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Balashov, K. E., Rottman, J. B., Weiner, H. L. & Hancock, W. W. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc. Natl Acad. Sci. USA 96, 6873–6878 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Makhlouf, K., Weiner, H. L. & Khoury, S. J. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J. Neuroimmunol. 119, 145–149 (2001).
  Article CAS PubMed Google Scholar
• Nicoletti, F. et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 57, 342–344 (2001).
  Article CAS PubMed Google Scholar
• Karni, A., Koldzic, D. N., Bharanidharan, P., Khoury, S. J. & Weiner, H. L. IL-18 is linked to raised IFN-γ in multiple sclerosis and is induced by activated CD4+ T cells via CD40–CD40 ligand interactions. J. Neuroimmunol. 125, 134–140 (2002).
  Article CAS Google Scholar
• Karni, A. et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-γ production of CD8+ T cells in secondary progressive multiple sclerosis. J. Neuroimmunol. 146, 189–198 (2004).
  Article CAS Google Scholar
• Soldan, S. S., Alvarez Retuerto, A. I., Sicotte, N. L. & Voskuhl, R. R. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J. Neuroimmunol. 146, 209–215 (2004).
  Article CAS PubMed Google Scholar
• Lopez, C., Comabella, M., Al-zayat, H., Tintore, M. & Montalban, X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J. Neuroimmunol. 175, 183–191 (2006).
  Article CAS PubMed Google Scholar
• Karni, A. et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177, 4196–4202 (2006).
  Article CAS PubMed Google Scholar
• Charo, I. F. & Ransohoff, R. M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610–621 (2006).
  Article CAS PubMed Google Scholar
• Ukkonen, M., Wu, K., Reipert, B., Dastidar, P. & Elovaara, I. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Mult. Scler. 13, 701–707 (2007).
  Article CAS PubMed Google Scholar
• Agrawal, S. M. & Yong, V. W. Immunopathogenesis of multiple sclerosis. Int. Rev. Neurobiol. 79, 99–126 (2007).
  Article CAS PubMed Google Scholar
• Loeb, J. A. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 68, S38–S42; discussion S43–S54 (2007).
  Article CAS PubMed Google Scholar
• Yong, V. W., Giuliani, F., Xue, M., Bar-Or, A. & Metz, L. M. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 68, S32–S37; discussion S43–S54 (2007).
  Article CAS PubMed Google Scholar
• Dutta, R. & Trapp, B. D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68, S22–S31; discussion S43–S54 (2007).
  Article Google Scholar
• Dhib-Jalbut, S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 68, S13–S21; discussion S43–S54 (2007).
  Article CAS Google Scholar
• Miller, D. H. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 1, 284–294 (2004).
  Article PubMed PubMed Central Google Scholar
• Bielekova, B. & Martin, R. Development of biomarkers in multiple sclerosis. Brain 127, 1463–1478 (2004).
  Article PubMed Google Scholar
• Jacobs, L. D. et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996).
  Article CAS PubMed Google Scholar
• Jacobs, L. D. et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343, 898–904 (2000). Pivotal clinical trial supporting the use of intramuscular IFNβ-1a therapy in RRMS.
  Article CAS PubMed Google Scholar
• Comi, G. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576–1582 (2001).
  Article CAS PubMed Google Scholar
• Paty, D. W. & Li, D. K. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43, 662–667 (1993).
  Article CAS PubMed Google Scholar
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498–1504 (1998).
• Panitch, H. et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59, 1496–1506 (2002).
  Article CAS PubMed Google Scholar
• Bornstein, M. B. et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317, 408–414 (1987).
  Article CAS PubMed Google Scholar
• Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995). Key clinical trial supporting glatiramer acetate use in RRMS.
  Article CAS PubMed Google Scholar
• Johnson, K. P. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50, 701–708 (1998). Follow-up clinical safety and efficacy data on glatiramer acetate use in RRMS.
  Article CAS PubMed Google Scholar
• Comi, G., Filippi, M. & Wolinsky, J. S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging — measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290–297 (2001). Supporting MRI data on glatiramer acetate's efficacy in RRMS activity reduction.
  Article CAS PubMed Google Scholar
• Ebers, G. C. & PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498–1504 (1998). Pivotal clinical trial supporting the use of IFNβ-1a in RRMS.
  Article CAS Google Scholar
• [No authors listed]. Randomized controlled trial of interferon- β-1a in secondary progressive MS: Clinical results. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-β-1a in MS Study Group). Neurology 56, 1496–1504 (2001). Clinical evidence on the use of IFNβ-1a in SPMS.
• Li, D. K., Zhao, G. J. & Paty, D. W. Randomized controlled trial of interferon-β-1a in secondary progressive MS: MRI results. Neurology 56, 1505–1513 (2001).
  Article CAS PubMed Google Scholar
• Calabresi, P. A. et al. An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology 58, 314–317 (2002).
  Article CAS PubMed Google Scholar
• Cohen J. et al. Rationale and design of the Avonex combination trial. Mult. Scler. 9 (Suppl. 1), S139–S140 (2003).
  Google Scholar
• Patti, F. et al. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-β study denomination: CYCLIN. J. Neurol. Sci. 223, 69–71 (2004).
  Article CAS PubMed Google Scholar
• Fernandez, O. et al. Combination therapy with interferon β-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study. J. Neurol. 249, 1058–1062 (2002).
  Article CAS PubMed Google Scholar
• Lus, G., Romano, F., Scuotto, A., Accardo, C. & Cotrufo, R. Azathioprine and interferon β1a in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol. 51, 15–20 (2004).
  Article CAS PubMed Google Scholar
• Calabresi, P. A. et al. An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology 62 (Suppl. 5), A491 (2004).
  Google Scholar
• Manneschi, L. et al. Interferon β1-b in combination with azathioprine for secondary progressive multiple sclerosis. Preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study. Neurology 62 (Suppl. 5), A487 (2004).
  Google Scholar
• Stuve, O. et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest. 116, 1037–1044 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ramtahal, J., Jacob, A., Das, K. & Boggild, M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J. Neurol. 253, 1160–1164 (2006).
  Article CAS PubMed Google Scholar
• Boggild M. Rationale and experience with combination therapies in multiple sclerosis. J. Neurol. 253 (Suppl. 6), VI/45–VI/51 (2006).
  CAS Google Scholar
• Tullman, M. J. & Lublin, F. D. Combination therapy in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 5, 245–248 (2005).
  Article CAS PubMed Google Scholar
• Weinstock-Guttman, B. & Bakshi, R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs 18, 777–792 (2004).
  Article CAS PubMed Google Scholar
• Martinelli, V. Combination therapy. Neurol. Sci. 27 (Suppl. 5), S350–S354 (2006).
  Article PubMed Google Scholar
• van der Mei, I. A. et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case–control study. BMJ 327, 316 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Hayes, C. E., Cantorna, M. T. & DeLuca, H. F. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216, 21–27 (1997).
  Article CAS PubMed Google Scholar
• Hayes, C. E., Nashold, F. E., Spach, K. M. & Pedersen, L. B. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49, 277–300 (2003).
  CAS Google Scholar
• Adorini, L., Penna, G., Giarratana, N. & Uskokovic, M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J. Cell Biochem. 88, 227–233 (2003).
  Article CAS PubMed Google Scholar
• Aubin, F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur. J. Dermatol. 13, 515–523 (2003).
  CAS PubMed Google Scholar
• Lemire, J. M. & Archer, D. C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103–1107 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Cantorna, M. T., Hayes, C. E. & DeLuca, H. F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl Acad. Sci. USA 93, 7861–7864 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Spach, K. M. & Hayes, C. E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 175, 4119–4126 (2005).
  Article CAS PubMed Google Scholar
• Soilu-Hanninen, M. et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11, 266–271 (2005).
  Article CAS PubMed Google Scholar
• Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832–2838 (2006).
  Article CAS PubMed Google Scholar
• Quintana, F. J. et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis Proc. Natl Acad. Sci. USA (in the press).